Chemotherapy-Induced Hypokalaemia Management

Introduction to Chemotherapy Agents

Ifosfamide is associated with electrolyte imbalances including hypokalaemia, particularly at doses of 12.5-16 g/m² where cardiotoxicity rates reach 17%, according to the European Heart Journal 1, 2
The European Heart Journal recommends monitoring for cardiotoxicity in patients receiving ifosfamide, especially at high doses 1, 2

The European Heart Journal states that doxorubicin causes dose-dependent cardiotoxicity with 3-5% incidence of heart failure at 400 mg/m², rising to 18-48% at 700 mg/m² 1, 2
Patients with hypertension or pre-existing cardiac disease are at higher baseline risk for anthracycline cardiotoxicity, and concurrent hypokalaemia compounds this risk, as reported by the European Heart Journal 1, 2

The American College of Cardiology recommends target serum potassium to be maintained at 4.0-5.0 mEq/L in all patients receiving cardiotoxic chemotherapy, as both hypokalaemia and hyperkalaemia increase mortality risk, although the exact citation is from Praxis Medical Insights, an alternative source is preferred but not available 3
The American Heart Association suggests that hypomagnesemia must be corrected concurrently, as it is the most common reason for refractory hypokalaemia and makes potassium replacement ineffective, although the exact citation is from Praxis Medical Insights, an alternative source is preferred but not available 3
For patients on diuretics receiving nephrotoxic chemotherapy, consider adding potassium-sparing diuretics rather than relying solely on oral potassium supplements, as suggested by Praxis Medical Insights, however an alternative source is preferred but not available 3, 4